Epilepsy Drugs Market | Global Industry 2018
Latest Pharmaceutical and Healthcare global epilepsy market pipeline provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.
Summery
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles.
Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.
Report Highlights
·
The Pharmaceutical and Healthcare latest pipeline guide
Epilepsy - Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Epilepsy (Central Nervous System), complete
with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases.
·
The Epilepsy (Central Nervous System) pipeline guide also
reviews of key players involved in therapeutic development for Epilepsy and
features dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules developed by
Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA
Filed, Preclinical, Discovery and Unknown stages are 7, 12, 15, 24, 1, 3, 69,
12 and 2 respectively. Similarly, the Universities portfolio in Preclinical and
Discovery stages comprises 18 and 2 molecules, respectively.
·
Epilepsy (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. The guide is built using data and
information sourced from the proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
Scope
·
The pipeline guide provides a snapshot of the global
therapeutic landscape of Epilepsy (Central Nervous System).
·
The pipeline guide reviews pipeline therapeutics for Epilepsy
(Central Nervous System) by companies and universities/research institutes
based on information derived from company and industry-specific sources.
·
The pipeline guide
covers pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
·
The pipeline guide
features descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details, R&D
brief, MoA & other developmental activities.
·
The pipeline guide reviews key companies involved in Epilepsy
(Central Nervous System) therapeutics and enlists all their major and minor
projects.
·
The pipeline guide evaluates Epilepsy (Central Nervous
System) therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
·
The pipeline guide encapsulates all the dormant and
discontinued pipeline projects.
·
The pipeline guide
reviews latest news related to pipeline therapeutics for Epilepsy (Central
Nervous System)
Reasons to buy
·
Procure strategically important competitor information,
analysis, and insights to formulate effective R&D strategies.
·
Recognize emerging
players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
·
Find and recognize significant and varied types of
therapeutics under development for Epilepsy (Central Nervous System).
·
Classify potential new clients or partners in the target
demographic.
·
Develop tactical initiatives by understanding the focus areas
of leading companies.
·
Plan mergers and acquisitions meritoriously by identifying
key players and it’s most promising pipeline therapeutics.
·
Formulate corrective measures for pipeline projects by
understanding Epilepsy (Central Nervous System) pipeline depth and focus of
Indication therapeutics.
·
Develop and design
in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and
scope.
·
Adjust the therapeutic portfolio by recognizing discontinued
projects and understand from the know-how what drove them from pipeline.
Category of Report:
Related
Reports:
Contact Details:
Aarkstore Enterprise
Phone: +91 - 22 2756 4963
24/7 Online Support: +91 9987295242
Email: contact@aarkstore.com
Phone: +91 - 22 2756 4963
24/7 Online Support: +91 9987295242
Email: contact@aarkstore.com
Our website: https://www.aarkstore.com
Comments
Post a Comment